EuroEyes International Eye Clinic Limited (1846) released a clarification and completion announcement regarding its discloseable transactions involving asset acquisitions in Switzerland and the United Kingdom. The announcement highlights refinements to prior disclosures, additional financial data, and confirms completion of the Swiss Agreement.
EuroEyes clarified the definition of the minority shareholders in its Swiss subsidiary and provided the shareholding structure upon completion. The subsidiary’s major shareholders now include EuroEyes International Eye Clinic Limited at approximately 79%, with two individuals each holding 4.5% and other minority shareholders holding 12%. A previously noted typographical error regarding the Swiss clinic, clarifying Basel rather than Lucerne, was also announced.
Financial information for the Swiss assets showed revenues of approximately CHF15.75 million in 2024 and CHF6.46 million for the first six months of 2025. Gross profit for the same periods was approximately CHF4.49 million and CHF1.36 million, respectively. Net profit before and after taxation for the years ended 31 December 2023 and 2024 and the six months ended 30 June 2025 was also disclosed, reflecting both positive and negative results over these periods.
Guidance on the UK assets addressed the net profit situation from 21 August 2023 to 31 December 2023 (when operations had yet to commence) and for subsequent periods during 2024 and 2025, with losses reported for the latter two intervals.
In terms of transaction details, a put option was granted to minority shareholders of the Swiss subsidiary. The exercise price was capped, providing a threshold for any potential future purchase of shares from the minority shareholders. This arrangement, together with the prior considerations, was deemed a discloseable transaction under the relevant Listing Rules.
The company confirmed that all conditions of the Swiss Agreement were satisfied, and completion took place on 13 October 2025. This included the transfer of certain ordinary shares to two individuals as part of compensation for their continued roles in running the Swiss business. All other terms and conditions of the original announcement remain unchanged.